glucagon vs glp-1 Glucagon-like peptide-1 GLP-1 Receptor Agonists – Peripheral
Description
Public comments on the MCL petition are due by August 29, 2025
By 2031, Eli Lilly's eloralintide is forecast to lead the pack, generating $3.4bn, followed by the $771m attributed to Novo Nordisk's cagrilintide
Sarhan.
If youve read my glucagon agonism article you know exactly where this is going
Coverage Review & Utilization Controls: Utilization management, such as step therapy or prior authorization for GLP-1s, is now commonplace to ensure use is appropriate and cost-effective
